Supplements
This product scores Average due to promising immune efficacy balanced against regulatory and quality concerns. Effectiveness (75) reflects robust PubMed evidence from reviews (e.g., PMID 33362999, 38308608) showing TA1 enhances T-cell maturation and cytokine production in trials for hepatitis (1.6mg 2x/week) and cancer, with over 11,000 patients demonstrating benefits, though general supplement claims lack RCTs. Safety (55) is tempered by FDA's Category 2 status for compounding risks (immunogeni
Thymosin Alpha 1 offers evidence-based immune support for specific conditions like viral infections or cancer adjunct, but its unapproved status and FDA compounding risks make it unsuitable as a general supplement. Use only under medical supervision with verified purity. Average rating reflects balanced efficacy against regulatory hurdles.